---
theme: academic
layout: cover
class: text-white
coverAuthor: beau hilton
coverAuthorUrl: https://www.beauhilton.com
coverDate: "2023-09-01"
themeConfig:
  paginationX: r
  paginationY: t
  paginationPagesDisabled: [1]
title: Induction Chemotherapy for HNSCC
info: |
  # Case Conference
  Case Conference 2023-09-01, [Beau Hilton](https://www.beauhilton.com)

---

# Induction Chemotherapy for Head and Neck Squamous Cell Carcinoma

---

# Case presentation

61M, previously healthy. Heavy smoker, quit a couple of months ago.

<v-clicks>

5 weeks of progressive facial pain.

Seen by local doctors, given antibiotics for a presumed sinus infection.

Purulent drainage.

Dentures stopped fitting.

Face started to go numb.

Admitted, biopsied.

Nasopharyngeal SCC, nonkeratinizing, discharged home.

</v-clicks>

---

# Case presentation

## Exam

<v-clicks>

Swollen left eye

Numb left cheek and lips


</v-clicks>

## Labs

<v-clicks>

mild anemia, mild leukocytosis, BMP and LFTs fine, really nothing interesting

</v-clicks>

---

# Imaging

Similar case on Radiopaedia:

<https://radiopaedia.org/cases/59258/studies/66600?lang=us>


---


# Questions

- What is induction? (What is the difference between induction and neoadjuvant therapy?)
- When is induction a good idea?
- When is it a bad idea?
- Why are the surgeons always asking us to induce?
- What regimens are available/have been studied?
- How do I select a regimen for a given patient and situation?


---


# induction chemotherapy (ICT) through the ages

## 1960s

<v-clicks>

- MTX

</v-clicks>

## 1970s

<v-clicks>

- MTX vs cisplatin (response rate 14-41%)
- cisplatin+bleomycin
- cisplatin+bleomycin+[MTX vs vinca]
  - cisplatin+bleomycin+vincristine response rate 80%, CR 29%
- cisplatin+5-FU (PF)
  - response rate 88%, CR 19%
- PF with 120h of 5-FU
  - response rate 93%, Cr 38%
- PF with 120h of 5-FU and higher dose of cisplatin
  - no benefit, more tox

</v-clicks>


---


# ICT through the ages

## 1980s

<v-clicks>

- 5x RCT w MTX - 4/5 -ve, 1/5 +ve only for stage II oral cavity disease (and used intra-arterial MTX)
- many other RCTs, no benefit (outside of limited stage oral cavity disease)

</v-clicks>

## 1990s

<v-clicks>

- Concurrent Cisplatin-based chemoRadioTherapy (CCRT)

<img src="/images/ICT_vs_CCRT_1990s.png" class="h-50 rounded "/>

</v-clicks>


---


# ICT through the ages


## 2000s

<v-clicks>

- PF vs TPF
- European study (TAX323) had RT afterward, American Study (TAX324) had CCRT afterward.

<br>
<img src="/images/TAX324_TAX323_20221209151920.png" class="h-80 rounded "/>

</v-clicks>


---


# ICT through the ages

## 2000s

<v-clicks>

- ICT + CCRT vs CCRT alone
- OS doesn't increase, toxicity does
<img src="/images/ICT_vs_CCRT_2000s.png" class="h-80 rounded "/>
- nuanced (locoregional vs distant recurrence)
- later meta-analyses suggest perhaps TPF+CCRT has benefit over CCRT alone (fitter patients?)

</v-clicks>


---


# ICT through the ages

## 2010s

<v-clicks>

Rise of the mods:

- modified TPF (dose reduced)
- weekly carbo-taxol followed by CCRT
- TPEx (cisplatin, docetaxel, cetuximab)

Our patient:

- docetaxel 75, cisplatin 75, q3wk x3 and reimage

</v-clicks>


---


# ICT today

<v-clicks>

- NPC
  - gem+cis ICT f/b CCRT: +OS benefit if EBV+ (NEJM 2019, JCO 2022)
- larynx preservation
  - CCRT not clearly better than ICT in pts who qualify for total laryngectomy but not partial - SALTORL trial is comparing ICT and CCRT head-to-head
- treatment intensification
  - TPF+CCRT in the fittest patients?
- converting borderline resectable to resectable
  - ~30% conversion rate
- oligometastatic disease
  - shrink/eliminate distant sites, spot weld prn, then CCRT/surgery?
- neurologic and airway compromise (i.e. true urgencies, nonoperable)
    - dental procedures wrt timing of RT, may need to start ICT to bridge until dental procedures are done plus ~2wks (h/t Ronak Mistry)

</v-clicks>

* https://www.nejm.org/doi/full/10.1056/NEJMoa1905287#:~:text=In%20conclusion%2C%20the%20addition%20of,risk%20locoregionally%20advanced%20nasopharyngeal%20cancer.
* https://pubmed.ncbi.nlm.nih.gov/35709465/

---

# ICT for NPC


<img src="/images/npc-ebv.png" class="h-80 rounded "/>

---

# Induction radiotherapy?

"Quad-shot" RT: 14-15 Gy over 4 fractions
- 2x/day (6h separation) x 2 days
- palliative
- if response, can continue monthly (usually cap around Gy in the low 40s)
- studies looking at quad-shot+something are ongoing (e.g. http://clinicaltrials.gov/study/NCT04454489 - +pembro)
---




---
layout: index
indexEntries:
  - { title: "HemOnc.org entry", uri: "https://hemonc.org/wiki/Head_and_neck_cancer#Locally_advanced_disease.2C_induction" }
  - { title: "NCCN Guidelines", uri: "https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1437" }
  - { title: "PathologyOutlines", uri: "https://www.pathologyoutlines.com/oralcavity.html" }
  - { title: "notes", uri: "https://notes.beauhilton.com/reference/vermorkenWhereWhenUse2021" }
indexRedirectType: external
---


# Resources


---


# Bibliography

<div class="csl-bib-body text-sm" style="line-height: 1.35; margin-left: 2em; text-indent:-2em;">
  <div class="csl-entry">Ferrari, Daris, Maria Grazia Ghi, Ciro Franzese, Carla Codecà, Max Gau, and Jerome Fayette. “The Slippery Role of Induction Chemotherapy in Head and Neck Cancer: Myth and Reality.” <i>Frontiers in Oncology</i> 10 (January 23, 2020): 7. <a href="https://doi.org/10.3389/fonc.2020.00007">https://doi.org/10.3389/fonc.2020.00007</a>.</div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_id=info%3Adoi%2F10.3389%2Ffonc.2020.00007&amp;rft_id=info%3Apmid%2F32038985&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=The%20Slippery%20Role%20of%20Induction%20Chemotherapy%20in%20Head%20and%20Neck%20Cancer%3A%20Myth%20and%20Reality&amp;rft.jtitle=Frontiers%20in%20Oncology&amp;rft.stitle=Front%20Oncol&amp;rft.volume=10&amp;rft.aufirst=Daris&amp;rft.aulast=Ferrari&amp;rft.au=Daris%20Ferrari&amp;rft.au=Maria%20Grazia%20Ghi&amp;rft.au=Ciro%20Franzese&amp;rft.au=Carla%20Codec%C3%A0&amp;rft.au=Max%20Gau&amp;rft.au=Jerome%20Fayette&amp;rft.date=2020-01-23&amp;rft.pages=7&amp;rft.issn=2234-943X"></span>
  <div class="csl-entry">Jacobs, John R., Thomas F. Pajak, Jeannie Kinzie, Muhyi Al-Sarraf, Lawrence Davis, Gerald A. Hanks, Irving Weigensberg, and Steven Leibel. “Induction Chemotherapy in Advanced Head and Neck Cancer: A Radiation Therapy Oncology Group Study.” <i>Archives of Otolaryngology–Head &amp; Neck Surgery</i> 113, no. 2 (February 1, 1987): 193–97. <a href="https://doi.org/10.1001/archotol.1987.01860020085018">https://doi.org/10.1001/archotol.1987.01860020085018</a>.</div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_id=info%3Adoi%2F10.1001%2Farchotol.1987.01860020085018&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Induction%20Chemotherapy%20in%20Advanced%20Head%20and%20Neck%20Cancer%3A%20A%20Radiation%20Therapy%20Oncology%20Group%20Study&amp;rft.jtitle=Archives%20of%20Otolaryngology%E2%80%93Head%20%26%20Neck%20Surgery&amp;rft.stitle=Archives%20of%20Otolaryngology%E2%80%93Head%20%26%20Neck%20Surgery&amp;rft.volume=113&amp;rft.issue=2&amp;rft.aufirst=John%20R.&amp;rft.aulast=Jacobs&amp;rft.au=John%20R.%20Jacobs&amp;rft.au=Thomas%20F.%20Pajak&amp;rft.au=Jeannie%20Kinzie&amp;rft.au=Muhyi%20Al-Sarraf&amp;rft.au=Lawrence%20Davis&amp;rft.au=Gerald%20A.%20Hanks&amp;rft.au=Irving%20Weigensberg&amp;rft.au=Steven%20Leibel&amp;rft.date=1987-02-01&amp;rft.pages=193-197&amp;rft.spage=193&amp;rft.epage=197&amp;rft.issn=0886-4470"></span>
  <div class="csl-entry">Okano, Susumu, Akihiro Homma, Naomi Kiyota, Makoto Tahara, Nobuhiro Hanai, Takahiro Asakage, Kazuto Matsuura, et al. “Induction Chemotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck.” <i>Japanese Journal of Clinical Oncology</i> 51, no. 2 (February 1, 2021): 173–79. <a href="https://doi.org/10.1093/jjco/hyaa220">https://doi.org/10.1093/jjco/hyaa220</a>.</div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_id=info%3Adoi%2F10.1093%2Fjjco%2Fhyaa220&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Induction%20chemotherapy%20in%20locally%20advanced%20squamous%20cell%20carcinoma%20of%20the%20head%20and%20neck&amp;rft.jtitle=Japanese%20Journal%20of%20Clinical%20Oncology&amp;rft.stitle=Japanese%20Journal%20of%20Clinical%20Oncology&amp;rft.volume=51&amp;rft.issue=2&amp;rft.aufirst=Susumu&amp;rft.aulast=Okano&amp;rft.au=Susumu%20Okano&amp;rft.au=Akihiro%20Homma&amp;rft.au=Naomi%20Kiyota&amp;rft.au=Makoto%20Tahara&amp;rft.au=Nobuhiro%20Hanai&amp;rft.au=Takahiro%20Asakage&amp;rft.au=Kazuto%20Matsuura&amp;rft.au=Takenori%20Ogawa&amp;rft.au=Yuki%20Saito&amp;rft.au=Daisuke%20Sano&amp;rft.au=Takeshi%20Kodaira&amp;rft.au=Atsushi%20Motegi&amp;rft.au=Koichi%20Yasuda&amp;rft.au=Shunji%20Takahashi&amp;rft.au=Kaoru%20Tanaka&amp;rft.au=Takuma%20Onoe&amp;rft.au=Tomoya%20Yokota&amp;rft.au=Yoshinori%20Imamura&amp;rft.au=Yosuke%20Ariizumi&amp;rft.au=Tetsuo%20Akimoto&amp;rft.au=Ryuichi%20Hayashi&amp;rft.date=2021-02-01&amp;rft.pages=173-179&amp;rft.spage=173&amp;rft.epage=179&amp;rft.issn=1465-3621"></span>
  <div class="csl-entry">Vermorken, Jan B. “Where and When to Use Induction Chemotherapy in Head and Neck Squamous Cell Cancer.” In <i>Critical Issues in Head and Neck Oncology</i>, edited by Jan B. Vermorken, Volker Budach, C. René Leemans, Jean-Pascal Machiels, Piero Nicolai, and Brian O’Sullivan, 155–79. Cham: Springer International Publishing, 2021. <a href="https://doi.org/10.1007/978-3-030-63234-2_11">https://doi.org/10.1007/978-3-030-63234-2_11</a>.</div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_id=info%3Adoi%2F10.1007%2F978-3-030-63234-2_11&amp;rft_id=urn%3Aisbn%3A978-3-030-63234-2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=proceeding&amp;rft.atitle=Where%20and%20when%20to%20Use%20Induction%20Chemotherapy%20in%20Head%20and%20Neck%20Squamous%20Cell%20Cancer&amp;rft.btitle=Critical%20Issues%20in%20Head%20and%20Neck%20Oncology&amp;rft.place=Cham&amp;rft.publisher=Springer%20International%20Publishing&amp;rft.aufirst=Jan%20B.&amp;rft.aulast=Vermorken&amp;rft.au=Jan%20B.%20Vermorken&amp;rft.au=Jan%20B.%20Vermorken&amp;rft.au=Volker%20Budach&amp;rft.au=C.%20Ren%C3%A9%20Leemans&amp;rft.au=Jean-Pascal%20Machiels&amp;rft.au=Piero%20Nicolai&amp;rft.au=Brian%20O%E2%80%99Sullivan&amp;rft.date=2021&amp;rft.pages=155-179&amp;rft.spage=155&amp;rft.epage=179&amp;rft.isbn=978-3-030-63234-2&amp;rft.language=en"></span>
</div>
